文献速递新药、器械与细胞基因治疗研发真实世界研究与卫生经济

美国公共部门对创新药物后期发现的资金支持:队列研究

Public sector financial support for late stage discovery of new drugs in the United States: cohort study.
PubMed 文献 · BMJ · 2019-10-23

该队列研究纳入2008年1月至2017年12月美国食品药品监督管理局(FDA)通过新药申请途径批准的全部含一个或多个新分子实体的新药,评估公共资金对药物后期开发的贡献。10年间共批准248种新药,其中48种(19%)源于公共支持的研究与开发,14种(6%)源于公共支持研究项目衍生公司;这些药物更可能获得FDA加速审批(68% vs 47%,P=0.005)或被认定为首创药物(45% vs 26%,P=0.007)。结论认为公共支持研究在至少四分之一新药的后期开发中发挥重要作用。

要点

  • 2008-2017年FDA批准248种新药,48种(19%)源于公共支持研发。
  • 14种(6%)新药源于公共支持研究项目的衍生公司。
  • 公共支持来源药物更易获加速审批(68% vs 47%,P=0.005)或首创认定(45% vs 26%,P=0.007)。

核心结论

  • 公共支持研究通过直接资助后期研究或公共研究机构衍生公司,在至少四分之一新药的后期开发中发挥主要作用。
  • 这些发现可能对政策制定者确定这些产品的公平价格和收入流有启示。

研究设计与样本

  • 队列研究,纳入2008年1月至2017年12月美国FDA通过新药申请途径批准的全部含一个或多个新分子实体的新药。
  • 主要结局指标为记录公共部门研究机构或衍生公司后期研究贡献的专利或药物开发历史,以及每个药物的监管审批途径和首创药物认定。

主要发现

  • 10年研究期间FDA批准248种含一个或多个新分子实体的药物。
  • 48种(19%)药物源于公共支持的研究与开发。
  • 14种(6%)药物源于公共支持研究项目衍生公司。
  • 上述两组药物更可能获得FDA加速审批(68% vs 47%,P=0.005)。
  • 上述两组药物更可能被认定为首创药物(45% vs 26%,P=0.007)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the extent to which late stage development of new drugs relies on support from public funding. DESIGN: Cohort study. SETTING: All new drugs containing one or more new molecular entities approved by the US Food and Drug Administration (FDA) between January 2008 and December 2017 via the new drug application pathway. MAIN OUTCOME MEASURES: Patents or drug development histories documenting late stage research contributions by a public sector research institution or a spin-off company, as well as each drug's regulatory approval pathway and first-in-class designation. RESULTS: Over the 10 year study period, the FDA approved 248 drugs containing one or more new molecular entities. Of these drugs, 48 (19%) had origins in publicly supported research and development and 14 (6%) originated in companies spun off from a publicly supported research program. Drugs in these groups were more likely to receive expedited FDA approval (68% v 47%, P=0.005) or be designated first in class (45% v 26%, P=0.007), indicating therapeutic importance. CONCLUSIONS: A review of the patents associated with new drugs approved over the past decade indicates that publicly supported research had a major role in the late stage development of at least one in four new drugs, either through direct funding of late stage research or through spin-off companies created from public sector research institutions. These findings could have implications for policy makers in determining fair prices and revenue flows for these products.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Nayak RK, Avorn J, Kesselheim AS, et al. Public sector financial support for late stage discovery of new drugs in the United States: cohort study. BMJ. 2019. PMID: 31645328. doi:10.1136/bmj.l5766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。